<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010304</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2021-0517</org_study_id>
    <nct_id>NCT05010304</nct_id>
  </id_info>
  <brief_title>Penicillin De-labeling in the Pediatric Primary Care Setting</brief_title>
  <official_title>Penicillin De-labeling in the Pediatric Primary Care Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American College of Allergy, Asthma and Immunology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      While reported adverse reactions to penicillins are common, most patients with a penicillin&#xD;
      allergy label can safely tolerate penicillins, and elective evaluation for penicillin allergy&#xD;
      has been recommended. For low-risk patients, direct oral challenge may be an optimal approach&#xD;
      as a delabeling strategy. However, there is a vast disparity between the number of patients&#xD;
      with a penicillin allergy label and practicing allergists in the United States, and&#xD;
      implementing outpatient primary care-based delabeling strategies in low-risk patients may&#xD;
      increase access to delabeling assessments. However, a recent survey of pediatricians&#xD;
      identified perceived barriers to implementing penicillin allergy evaluations into their&#xD;
      routine care. Significant gaps in knowledge exist regarding the feasibility of this approach&#xD;
      involving risk stratification evaluation of reported penicillin adverse reactions and direct&#xD;
      amoxicillin challenge procedures in low-risk patients in the pediatric primary care setting.&#xD;
      With this, the primary aim of this study is to evaluate the number of patients for which&#xD;
      risk-stratification and direct amoxicillin challenge are successfully completed in an&#xD;
      outpatient pediatric primary care clinic.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subjects who complete risk-stratification of penicillin allergy in the pediatric primary care setting</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subjects stratified as low-risk with a negative immediate amoxicillin challenge in the pediatric primary care setting</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Penicillin allergy labeling in subjects with negative amoxicillin challenge</measure>
    <time_frame>10-14 months after amoxicillin challenge</time_frame>
    <description>Subjects who have a penicillin allergy label added back to their electronic health record at 10-14 months after amoxicillin challenge.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Penicillin Allergy</condition>
  <condition>Penicillin Reaction</condition>
  <arm_group>
    <arm_group_label>Pediatric Patients with a history of penicillin allergy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Two-dose amoxicillin challenge</description>
    <arm_group_label>Pediatric Patients with a history of penicillin allergy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children from ages 2-18 years with a history of parent-reported penicillin allergy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children with a history of reaction consistent with a severe cutaneous adverse&#xD;
             reaction to penicillin as defined as a history of oral blisters, diffuse skin peeling&#xD;
             or blisters after taking a penicillin, or having the diagnosis of Stevens Johnson&#xD;
             Syndrome, Toxic Epidermal Necrolysis, Drug rash with eosinophilia and systemic&#xD;
             symptoms will be excluded. Pregnant and breastfeeding female subjects will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children's Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Timothy Chow, MD</last_name>
    </contact>
    <investigator>
      <last_name>Timothy Chow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Timothy Chow</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>penicillin</keyword>
  <keyword>allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

